Metabolic Effects and Treatment Mechanisms in Major Depression

Major depressive disorder is increasingly understood as a multifaceted condition in which systemic and neural metabolism intersect with mood regulation. Perturbations in mitochondrial energy production, lipid transport and oxidative balance co-occur with alterations in glucose homeostasis and insulin signalling to undermine synaptic plasticity and resilience. Lower circulating levels of acylcarnitines and their derivatives reflect impaired fatty acid shuttle into mitochondria, while shifts in tricarboxylic acid cycle intermediates and amino‐acid metabolites map onto symptom clusters such as anhedonia and fatigue. Chronic inflammation and redox imbalance further compromise neuronal integrity and promote epigenetic reprogramming that sustains depressive states. Building on these insights, novel treatment mechanisms now focus on restoring neuroenergetics, modulating epigenetic marks and controlling neuroinflammation. Compounds that boost mitochondrial function, regulate carnitine metabolism or directly influence chromatin acetylation offer the promise of faster onset and greater efficacy, particularly in subtypes associated with childhood adversity or metabolic comorbidity.

Research from Nature Portfolio

Recent studies have demonstrated that prenatal and early‐life stress orchestrate long‐term changes in brain metabolism by altering both mitochondrial function and the epigenetic landscape. Experimental models reveal that trauma in pregnancy elevates mitochondrial hypoxia markers and disrupts key metabolic pathways in offspring, manifesting as social deficits and depression‐like behaviours in adulthood. These alterations are accompanied by broad rewiring of the brain metabotranscriptome and persistent changes in DNA and chromatin modification enzymes. Notably, early administration of acetyl-L-carnitine mitigated these behavioural and molecular sequelae, indicating that targeted metabolic supplementation can confer durable resilience against stress-induced depression.

Metabolic Effects and Treatment Mechanisms in Major Depression publication trend

The graph below shows the total number of articles in metabolic effects and treatment mechanisms in major depression across all publications each year (not limited to Nature Index journals).

Technical terms

Acetyl-L-carnitine (ALC): A mitochondrial metabolite that facilitates fatty acid transport into mitochondria and serves as an epigenetic modulator by donating acetyl groups to histones.

Acylcarnitines: Fatty acid–carnitine conjugates that reflect mitochondrial β-oxidation capacity and energy-metabolic health.

Metabotranscriptome: The integrated profile of metabolic intermediates and gene-expression changes that underlie cellular function and response to stress.

Epigenetic modulation: The regulation of gene activity via chemical modifications of DNA or histone proteins without altering the DNA sequence.

Oxidative balance: The equilibrium between reactive oxygen species production and antioxidant defences, critical for maintaining neuronal function.

References

1. Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort. Translational Psychiatry (2025).
2. L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review. Nutrients (2024).
3. Epigenetic embedding of childhood adversity: mitochondrial metabolism and neurobiology of stress-related CNS diseases. Frontiers in Molecular Neuroscience (2023).
4. Intergenerational trauma transmission is associated with brain metabotranscriptome remodeling and mitochondrial dysfunction. Communications Biology (2021).
5. Non-targeted Metabolomics Profiling of Plasma Samples From Patients With Major Depressive Disorder. Frontiers in Psychiatry (2022).
6. The neuropsychopharmacology of acetyl-L-carnitine (LAC): basic, translational and therapeutic implications. Discover Mental Health (2024).